Skip to main content
Retour
Watch Compare

Cadrenal Therapeutics, Inc.

Qualité des données : 83%
CVKD
NASDAQ Manufacturing Chemicals
4,81 €
▲ 0,02 € (0,42%)
6 months return
—
Momentum
Neutral
ROE
-376,39%

Croissance

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Qualité

Return on Equity
-376,39%
En dessous de la moyenne du secteur (-54,68%)
ROIC-302,38%
Net MarginN/A
Op. MarginN/A

Sécurité

Debt / Equity
N/A
Current Ratio3,02
Interest CoverageN/A

Valorisation

PE (TTM|NTM)
-0,92 | -1,22
Au-dessus de la moyenne du secteur (-1,49)
P/B Ratio4,46
EV/EBITDAN/A
Dividend YieldN/A

Quick Summary

Key Takeaways

Short bullets derived from reported financials—not the AI summary above.

Negative free cash flow of -12,61 M

Price History

Tendances Financières

Objectif de Cours des Analystes

3 analystes
Buy
+475.2%
upside to target
Actuel
4,81 €
Consensus Target
27,67 €
13,00 €
Bas
45,00 €
Haut
Prévisions
P/E Prévisionnel
-1,22
BPA Prévisionnel
-3,91 €
CA Est.
0,0

Surprises de Résultats

EPS
Reported Estimate Forecast
Next: Q1 2026 · EPS Est: -1,58 € · Rev Est: 0,0
Q12025 Q22025 Q32025 Q42025 Q1 '26 Q2 '26
Reported -2,09 € -1,87 € -1,31 € -1,41 € — —
Estimate -2,15 € -1,78 € -1,55 € -1,21 € -1,58 € -1,64 €
Surprise +2,79% -5,35% +15,48% -16,53% — —

Growth

Rev 5Y: N/A · Earnings 1Y: N/A
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A

Profitability

ROE: -376,39% · Net Margin: N/A
Revenue (TTM) N/A Net Income (TTM) -13,24 M
ROE -376,39% ROA -263,01%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -12,61 M
ROIC -302,38% FCF Growth (3Y) N/A

Safety

D/E: N/A · Current: 3,02
Debt / Equity N/A Current Ratio 3,02
Interest Coverage N/A Asset Turnover N/A
Working Capital 2,73 M Tangible Book Value 2,73 M

Dividends

Yield: N/A · Payout: N/A
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A

Valuation

P/E: -0,92 · EV/EBITDA: N/A
P/E Ratio -0,92 Forward P/E -1,22
P/B Ratio 4,46 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -103,44%
Market Cap 12,19 M Enterprise Value 8,33 M

Per Share

EPS: -6,64 · FCF/Share: -5,03
EPS (Diluted TTM) -6,64 Revenue / Share N/A
FCF / Share -5,03 OCF / Share -5,03
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A

Efficiency

FCF Conv: 95,24% · CapEx/Rev: N/A
CapEx / Revenue N/A FCF Conversion 95,24%
SBC-Adj. FCF -14,52 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2022 FY2023
Revenue — — — —
Net Income -13,24 M -10,65 M -6,71 M -8,36 M
EPS (Diluted) -6,64 -8,73 -0,85 -0,62
Gross Profit — — — —
Operating Income -13,46 M -10,96 M -2,70 M -7,63 M
EBITDA — — — —
R&D Expenses 4,10 M 4,21 M 136 802,0 4,08 M
SG&A Expenses — — — —
D&A — — — —
Interest Expense — 3 534,0 40 192,0 —
Income Tax — — — —

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2022 FY2023
Total Assets 4,33 M 10,12 M 778 174,0 8,52 M
Total Liabilities 1,59 M 2,68 M 6,33 M 826 875,0
Shareholders' Equity 2,74 M 7,44 M -5,55 M 7,69 M
Total Debt — — — —
Cash & Equivalents 4,01 M 10,00 M — 8,40 M
Current Assets 4,32 M 10,11 M 727 596,0 8,49 M
Current Liabilities 1,59 M 2,68 M 1,33 M 826 875,0

Comparaison Sectorielle

vs médiane du secteur Manufacturing (1605 pairs)
Métrique Action Médiane du Secteur
P/E -0,9 -1,5
P/B 4,5 1,6
ROE % -376,4 -54,7
Net Margin % — -41,5
Rev Growth 5Y % — 1,8
D/E — 0,3